FRIENDSWOOD, Texas–(BUSINESS WIRE)– Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its Chief Operating Officer, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023. The honorees “stand as a driving force, ensuring diverse perspectives on scientific breakthroughs and groundbreaking therapies,” according to the publication. “Their achievements serve as inspiration, paving the way for future generations of women leaders in biotech to continue shaping the future of healthcare.”
Kristen Oelschlager
“I am immensely proud of Kristen for earning this designation,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “As one of our company’s founders, Kristen has been invaluable to the success of our organization. To be honored among the nation’s elite women leaders in biotechnology is a testament to her fortitude and tenacious leadership.”
Oelschlager joined Castle Biosciences in 2008 as the executive director of operations, being promoted to vice president of clinical operations in 2013, senior vice president of clinical operations in 2018 and to her current role of chief operating officer in 2021. Her extensive background of more than 15 years in clinical nursing, clinical operations services and clinical research brought a unique perspective that has been instrumental in Castle’s success and growth from an early start-up to a thriving public company with almost 600 employees. Additionally, she has been influential in shaping the Company’s strategy and people-first culture, which have, in turn, helped garner Castle’s designation as a national Top Workplace for the last two consecutive years.
Oelschlager is one of the company’s three founders, alongside President and CEO, Derek Maetzold, and Chief Commercial Officer, Toby Juvenal.
The comprehensive list of the Top 25 Women Leaders in Biotechnology of 2023 can be viewed here.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
About The Healthcare Technology Report
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on healthcare technology and the various companies, executives and investors that make up the sector.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.